Newsfile Corp
28 Jul 2026, 13:48 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Regeneron's Phase III Fianlimab-Libtayo study failed to reach statistical significance for its primary endpoint of improvement in progression-free survival (PFS). — Failure of a Phase III trial is a major clinical setback that removes a potential future revenue stream and affects long-term valuation.
-0.80A federal securities class action lawsuit has been filed against Regeneron alleging the company made false or misleading statements regarding the Fianlimab-Libtayo study. — Securities litigation introduces legal uncertainty, potential large financial settlements, and reputational risk.
-0.40The lawsuit claims Regeneron concealed that the trial's preliminary statistical assumptions were flawed and that the treatment failed to show meaningful differentiation over standard therapies. — Allegations of intentional concealment of data are more damaging than simple trial failure as they suggest systemic management or reporting issues.
-0.30Continue reading
6 related stories
Top 2 movers · tap to explore
Which stocks this story touches
The company is facing a federal securities class action lawsuit following the failure of a Phase III clinical trial and allegations of misleading investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
2h ago
